664 related articles for article (PubMed ID: 28211251)
1. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
Hu H; Luan L; Yang K; Li SC
Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
[TBL] [Abstract][Full Text] [Related]
2. Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project.
Hallert E; Husberg M; Kalkan A; Skogh T; Bernfort L
Scand J Rheumatol; 2014; 43(3):177-83. PubMed ID: 24354438
[TBL] [Abstract][Full Text] [Related]
3. Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study.
Zhu TY; Tam LS; Li EK
Rheumatology (Oxford); 2011 Jul; 50(7):1293-301. PubMed ID: 21330341
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.
Osiri M; Maetzel A; Tugwell P
J Rheumatol; 2007 Jan; 34(1):57-63. PubMed ID: 17183621
[TBL] [Abstract][Full Text] [Related]
5. Societal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study.
Xu C; Wang X; Mu R; Yang L; Zhang Y; Han S; Li X; Wang Y; Wang G; Zhu P; Jin H; Sun L; Chen H; Cui L; Zhang Z; Li Z; Li J; Zhang F; Lin J; Liu X; Hu S; Yang X; Lai B; Li X; Wang X; Su Y; Li Z
Arthritis Care Res (Hoboken); 2014 Apr; 66(4):523-31. PubMed ID: 24023001
[TBL] [Abstract][Full Text] [Related]
6. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?
Eriksson JK; Johansson K; Askling J; Neovius M
Ann Rheum Dis; 2015 Apr; 74(4):648-54. PubMed ID: 24323395
[TBL] [Abstract][Full Text] [Related]
7. The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey.
Malhan S; Pay S; Ataman S; Dalkilic E; Dinc A; Erken E; Ertenli I; Ertugrul E; Gogus F; Hamuryudan V; Inanc M; Karaarslan Y; Karadag O; Karakoc Y; Keskin G; Kisacik B; Kiraz S; Oksel F; Oksuz E; Pirildar T; Sari I; Soy M; Senturk T; Taylan A
Clin Exp Rheumatol; 2012; 30(2):202-7. PubMed ID: 22546069
[TBL] [Abstract][Full Text] [Related]
8. Evolution of cost structures in rheumatoid arthritis over the past decade.
Huscher D; Mittendorf T; von Hinüber U; Kötter I; Hoese G; Pfäfflin A; Bischoff S; Zink A;
Ann Rheum Dis; 2015 Apr; 74(4):738-45. PubMed ID: 24406543
[TBL] [Abstract][Full Text] [Related]
9. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
[TBL] [Abstract][Full Text] [Related]
10. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
Her M; Kavanaugh A
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
[TBL] [Abstract][Full Text] [Related]
11. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
12. Direct, indirect and intangible costs of acute hand and wrist injuries: A systematic review.
Robinson LS; Sarkies M; Brown T; O'Brien L
Injury; 2016 Dec; 47(12):2614-2626. PubMed ID: 27751502
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
Phanthunane P; Whiteford H; Vos T; Bertram M
J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
[TBL] [Abstract][Full Text] [Related]
14. Indirect costs of rheumatoid arthritis in Brazil.
de Azevedo AB; Ferraz MB; Ciconelli RM
Value Health; 2008; 11(5):869-77. PubMed ID: 18489511
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of irritable bowel syndrome in China.
Zhang F; Xiang W; Li CY; Li SC
World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
[TBL] [Abstract][Full Text] [Related]
16. [Survey of economic burden of hepatitis B-related diseases in 12 areas in China].
Ma QS; Liang S; Xiao HW; Zhang SX; Zhuang GH; Zou YH; Tan HZ; Liu JC; Zhang YH; Xu AQ; Zhang L; Feng XX; Hu DS; Wang FZ; Cui FQ; Liang XF
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):868-876. PubMed ID: 28738457
[No Abstract] [Full Text] [Related]
17. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
[TBL] [Abstract][Full Text] [Related]
18. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.
Kvamme MK; Lie E; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2012 Sep; 51(9):1618-27. PubMed ID: 22539479
[TBL] [Abstract][Full Text] [Related]
19. The costs of rheumatoid arthritis.
Allaire SH; Prashker MJ; Meenan RF
Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
[TBL] [Abstract][Full Text] [Related]
20. [Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China].
Liang S; Zhang SX; Ma QS; Xiao HW; Lü QY; Xie X; Mei SJ; Hu DS; Zhou BP; Li B; Chen JF; Cui FQ; Wang FZ; Liang XF
Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1340-5. PubMed ID: 21223660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
